# Lupin: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Lupin Limited · NSE: LUPIN · BSE: 500257 · Sector: Healthcare

Updated for Q2 FY27 · checked 17 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/lupin. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Lupin: how the business works", with the page URL.

## In short

Buyers in more than 100 markets, most of all the US and India, pay Lupin for its medicines. Materials, running costs and staff take most of the money, and ₹18.8 of every ₹100 that came in was left as profit in FY26.

- In FY26 customers in the US gave 41.7% of Lupin's product revenue, India 29.6% and other countries 28.6%.
- Of every ₹100 that came in during FY26, ₹25.8 went on materials and goods bought, ₹25.5 on other running costs and ₹16.1 on staff.

## Key facts

**What does Lupin do?**

Lupin Ltd is a Mumbai-based drug maker founded in 1968. It sells generic medicines in the US and other countries and branded prescription medicines in India. Its FY26 revenue from operations was ₹27,958 crore, and it says it has 15 manufacturing sites and sells in more than 100 markets. [S1, S7, S18]

**How does Lupin make money?**

Lupin sells medicines. In its own FY26 sales figures, US sales were ₹11,678 crore (US$1,318 million), India ₹8,114 crore, emerging markets ₹3,483 crore, other developed markets ₹3,244 crore and active pharmaceutical ingredients (API) ₹969 crore. [S20]

**Who are Lupin's customers?**

By customer location, Lupin's FY26 product revenue came 41.7% from the US, 29.6% from India and 28.6% from other countries. Lupin's largest customer, a US buyer it does not name, gave ₹2,948 crore, 10.5% of Lupin's FY26 revenue from operations. [S1]

**How big is Lupin?**

Lupin's FY26 revenue from operations was ₹27,958 crore, up from ₹22,708 crore in FY25, and its profit for shareholders was ₹5,333 crore, up from ₹3,282 crore. Lupin says it employs more than 26,000 people. [S7, S11, S18]

**Who owns Lupin?**

On 30 Sep 2026 Lupin's promoter group held 46.84% of the shares. Foreign institutions held 23.28%, Indian institutions 23.78% (mutual funds 14.58%) and other shareholders 6.09%. No promoter shares were pledged. [S32]

**How did Lupin do in Q2 FY27?**

In Q2 FY27 (Jul–Sep 2026) Lupin's revenue was ₹7,827 crore, up from ₹7,048 crore a year earlier, and profit for shareholders was ₹1,155 crore, down from ₹1,478 crore. Lupin's US sales were US$317 million in Q2 FY27, against US$366 million in Q1 FY27. [S5, S9, S18]

**How much debt does Lupin have?**

On 30 Sep 2026 Lupin had borrowings of ₹5,496 crore and cash, bank deposits and current investments of ₹7,543 crore, so it held ₹2,047 crore more in cash than it owed (Cityfort calculation from the Q2 FY27 results). ICRA reaffirmed Lupin's short-term rating at [ICRA]A1+ on 8 Jul 2026. [S5, S31]

**What dividend does Lupin pay?**

Lupin's board recommended a dividend of ₹18 per share for FY26, up from ₹12 for FY25 and ₹8 for FY24. The FY26 dividend was 15.4% of Lupin's FY26 basic earnings per share of ₹116.75 (Cityfort calculation). [S20, S7, S2, S3]

## What does Lupin sell?

Lupin makes medicines. In the US it mostly sells generics: cheaper copies of medicines whose patents have expired. In India it sells brands that doctors prescribe. It also sells in Europe, Canada, emerging markets and to other drug makers.

- **Generic medicines in the US:** Off-patent medicines sold to US buyers: ₹11,678 crore in FY26 (US$1,318 million), against US$944 million in FY25. Lupin sold 149 generic products in the US in Q2 FY27, and says it was 3rd in US generics by prescriptions in Sep 2026 (IQVIA data). [S20, S18, S26]
- **Branded medicines in India:** Brands that doctors in India prescribe: ₹8,114 crore in FY26. Lupin says it ranks 8th in the Indian medicine market (IQVIA, Sep 2026), 2nd in breathing (respiratory) and 3rd in heart (cardiac) medicines. [S20, S18, S26]
- **Other developed markets:** Medicines sold in developed markets outside the US, including Canada and, since 1 Apr 2026, VISUfarma's eye-care brands in Italy, the UK, Spain, Germany and France: ₹3,244 crore in FY26. [S20, S44, S45]
- **Emerging markets:** Medicines sold in emerging markets: ₹3,483 crore in FY26. On 1 Jul 2026 Lupin raised its stake in Multicare Pharmaceuticals Philippines from 56.28% to 99.89%. [S20, S5]
- **Drug ingredients (API):** Active pharmaceutical ingredients, the chemical in a medicine that makes it work, sold to other drug makers: ₹969 crore in FY26, 3.5% of product sales. [S20]
- **Diagnostics and digital health:** Lupin's 'Others' segment, which covers diagnostics, digital health and neuro-rehabilitation: ₹147 crore of revenue in FY26 and a segment loss of ₹178 crore. [S1]

## Who pays Lupin?

- **Customers in the US (41.7% of revenue):** Buyers of Lupin's generic medicines in the US: ₹11,469 crore of FY26 product revenue, against ₹5,524 crore in FY22. The largest of them, not named, gave 10.5% of FY26 revenue. [S1, S4]
- **Customers in India (29.6% of revenue):** Buyers in India of Lupin's prescription brands and drug ingredients: ₹8,148 crore of FY26 product revenue. [S1]
- **Customers in other countries (28.6% of revenue):** Buyers in Canada, Europe, emerging markets and other countries: ₹7,871 crore of FY26 product revenue. [S1, S20]
- **Customer concentration:** largest customer 10.5% of revenue. Lupin's largest customer, a US buyer it does not name, gave ₹2,948 crore in FY26, 10.5% of revenue from operations. That share was 5.3% in FY22, 5.8% in FY23, 7.1% in FY24 and 8.6% in FY25. Shares above are of product revenue by customer location (₹27,488 crore). [S1, S3, S4]

## Where the money went (FY26)

1. In FY26 Lupin's medicines brought in ₹27,958 crore of revenue, and other income added ₹424 crore.
2. Materials and goods bought for resale took ₹7,327 crore, staff ₹4,575 crore and other running costs ₹7,241 crore.
3. Depreciation, amortisation and interest took ₹1,810 crore, and one-off charges ₹558 crore.
4. Income tax took ₹1,517 crore, and minority shareholders in subsidiaries ₹23 crore.
5. What was left for Lupin's shareholders was ₹5,333 crore of profit.

Sources: S7, S1, S8.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 | 16,406 | 287 | 1.8% | −1,528 | −9.3% | −33.65 | 367 | 905 | −538 | S16, S4 |
| FY23 | 16,642 | 1,798 | 10.8% | 430 | 2.6% | 9.46 | 1,897 | 1,500 | 398 | S15, S3 |
| FY24 | 20,011 | 3,811 | 19.0% | 1,915 | 9.6% | 42.05 | 3,648 | 929 | 2,720 | S14, S2 |
| FY25 | 22,708 | 5,283 | 23.3% | 3,282 | 14.5% | 71.95 | 3,000 | 1,682 | 1,318 | S11, S1 |
| FY26 | 27,958 | 8,258 | 29.5% | 5,333 | 19.1% | 116.75 | 7,335 | 2,055 | 5,280 | S7, S1 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of 30 Sep 2026, ₹ crore)

On 30 Sep 2026 Lupin's cash and liquid investments were ₹2,047 crore more than its borrowings (Cityfort calculation), down from ₹3,320 crore on 31 Mar 2026. [S5, S7, S11, S14, S1, S18, S20, S27]

| Item | Value |
| --- | --- |
| Total debt | 5,496 |
| Cash and investments | 7,543 |
| Net debt (debt minus cash) | −2,047 |
| Net worth (shareholders' money) | 24,051 |
| Debt to equity (times) | 0.23 |

- Cash and liquid investments = cash, other bank balances and current investments; net debt = borrowings minus that (Cityfort calculation). Lease liabilities (₹706 crore on 31 Mar 2026) are not included.
- The company's own figure, whose definition it does not give, was net cash of ₹3,349 crore on 30 Sep 2026 and ₹4,636 crore on 31 Mar 2026. Management linked the fall to the VISUfarma purchase and dividend payments.
- Borrowings were ₹2,670 crore on 31 Mar 2024, ₹5,077 crore on 31 Mar 2025 and ₹5,910 crore on 31 Mar 2026.
- Goodwill and other intangible assets were ₹7,941 crore on 30 Sep 2026, against ₹5,866 crore on 31 Mar 2026, after the VISUfarma purchase (Cityfort calculation).
- Contingent liabilities on 31 Mar 2026 included ₹151 crore of income-tax claims and ₹635 crore of guarantees for subsidiaries; for the US antitrust cases the company says an estimate of possible loss cannot be made.

## Who owns Lupin? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 46.84% |
| Promoter shares pledged (% of promoter shares) | 0.0% |
| Foreign institutions (FII) | 23.28% |
| Indian institutions (DII) | 23.78% |
| Public | 6.09% |

Sources: S43, S42, S41, S40, S39, S38, S37, S36, S35, S34, S33, S32.

## What could go wrong

### US prices fall when rivals launch

US sales were US$317 million in Q2 FY27, down 13.4% from Q1 FY27 in constant currency, as competition rose for Mirabegron and Tolvaptan. Management said on 4 Nov 2026 that margins were likely to moderate in the coming quarters. [S27, S18, S19]

What to watch: US sales in dollars each quarter (US$366 million in Q1 FY27, US$317 million in Q2 FY27).

### US FDA inspections

Three sites were under remediation in Q2 FY27, and ICRA said two had outstanding FDA warning letters. The Goa plant's FDA inspection ended with a one-observation Form 483 on 23 Oct 2026. [S26, S31, S52]

What to watch: FDA inspection results and Lupin's filings on Tarapur, Mandideep, Pithampur and the Goa Form 483.

### US antitrust cases

The US generic-drug pricing investigation (since 2017) and state lawsuits (since 2019) are open; Lupin says it cannot estimate the possible loss. It booked ₹582 crore of provisions in FY26, and FY22's ₹1,528 crore loss included a ₹1,878 crore settlement in a separate US case over Glumetza. [S1, S7, S4]

What to watch: New provisions or settlements in the notes to each quarter's results.

### One large US customer

Lupin's largest customer, an unnamed US buyer, gave 10.5% of FY26 revenue, up from 5.3% in FY22. [S1, S4]

What to watch: The largest-customer share in each annual report.

### Mirabegron licence costs and rivals

Lupin pays Astellas a per-unit licence fee on Mirabegron through Sep 2027, under the Feb 2026 settlement. Management said in Nov 2026 it expects more Mirabegron competition after Sep 2027. [S47, S27]

What to watch: Mirabegron comments in each call and US sales after Sep 2027.

### Paying for acquisitions

Lupin paid ₹2,090 crore for VISUfarma in Apr 2026 and ₹370 crore to raise its Multicare Philippines stake to 99.89% in Jul 2026. Goodwill and other intangible assets rose to ₹7,941 crore on 30 Sep 2026 (Cityfort calculation). [S5, S45, S46]

What to watch: Other developed markets sales each quarter and any write-down of goodwill or intangibles.

### Currency swings

US customers gave 41.7% of FY26 product revenue. Foreign-exchange gains in the company's figures were ₹87 crore in Q2 FY27, against ₹204 crore in Q2 FY26. [S1, S18]

What to watch: The rupee–dollar rate and the forex line in each results release.

## What to watch

Next: Q3 FY27 results, 12 Feb 2027 (expected).

- **US sales in dollars:** US$317 million in Q2 FY27 and US$683 million for the half year; management's FY27 range, given on 7 Aug 2026, is US$1.1 billion to US$1.2 billion.
- **FDA plant status:** Tarapur, Mandideep Unit-1 and Pithampur Unit-II were under remediation in Q2 FY27, and Goa got a one-observation Form 483 in Oct 2026.
- **Margins:** The company's own EBITDA margin, excluding forex gains and other income, was 25.1% in Q2 FY27, against 31.3% a year earlier; its FY27 guidance, given on 4 Nov 2026, is around 24–25%.

## Sources

- S1: Integrated Report (Annual Report) FY26. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/annual_reports/AR_29769_LUPIN_2025_2026_A_22791410_13072026201318.pdf (published 13 Jul 2026)
- S2: Integrated Report (Annual Report) FY25 (revised upload). Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/annual_reports/AR_27089_LUPIN_2024_2025_U_23072025223500.pdf (published 23 Jul 2025)
- S3: Integrated Report (Annual Report) FY24. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/annual_reports/AR_24389_LUPIN_2023_2024_0907202419738.pdf (published 9 Jul 2024)
- S4: Integrated Report (Annual Report) FY23. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/annual_reports/AR_22313_LUPIN_2022_2023_12072023235514_07132023070000.zip (published 12 Jul 2023)
- S5: Q2 FY27 consolidated results (XBRL), quarter and half year to 30 Sep 2026. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752380_04112026013306_WEB.xml (published 4 Nov 2026)
- S6: Q1 FY27 consolidated results (XBRL), quarter to 30 Jun 2026. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1709478_06082026102614_WEB.xml (published 6 Aug 2026)
- S7: Q4 FY26 and FY26 audited consolidated results (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1664747_07052026113234_WEB.xml (published 7 May 2026)
- S8: Q3 FY26 consolidated results (XBRL), quarter to 31 Dec 2025. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1624718_12022026100049_WEB.xml (published 12 Feb 2026)
- S9: Q2 FY26 consolidated results (XBRL), quarter to 30 Sep 2025. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1567369_06112025080309_WEB.xml (published 6 Nov 2025)
- S10: Q1 FY26 consolidated results (XBRL), quarter to 30 Jun 2025. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1503476_05082025092840_WEB.xml (published 5 Aug 2025)
- S11: Q4 FY25 and FY25 audited consolidated results (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1439448_15052025101010_WEB.xml (published 15 May 2025)
- S12: Q3 FY25 consolidated results (XBRL), quarter to 31 Dec 2024. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_119795_1379185_12022025122002.xml (published 12 Feb 2025)
- S13: Q2 FY25 consolidated results (XBRL), quarter to 30 Sep 2024. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_114437_1300634_07112024085454.xml (published 7 Nov 2024)
- S14: Q4 FY24 and FY24 audited consolidated results (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_105369_1116746_07052024010652.xml (published 7 May 2024)
- S15: Q4 FY23 and FY23 audited consolidated results (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_91432_839909_10052023121710.xml (published 10 May 2023)
- S16: Q4 FY22 and FY22 audited consolidated results (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_84742_656475_19052022112857_WEB.xml (published 19 May 2022)
- S17: Outcome of board meeting: unaudited results for the quarter and half year ended 30 Sep 2026. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_04112026004100_SE_Outcome_UFR_Intimation.pdf (published 4 Nov 2026)
- S18: Press release: Lupin Q2 FY2027 Results. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_04112026014246_SE_Intimation_Press_Release_04112026.pdf (published 4 Nov 2026)
- S19: Press release: Lupin Q1 FY2027 Results. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_06082026215741_SE_Intimation_Press_Release.pdf (published 6 Aug 2026)
- S20: Press release: Lupin FY2026 and Q4 FY2026 Results. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_07052026212907_SE_Intimation_Press_Release07052026.pdf (published 7 May 2026)
- S21: Press release: Lupin Q3 FY2026 Results. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_12022026223852_Lupin_Q3FY26_Press_Release.pdf (published 12 Feb 2026)
- S22: Press release: Lupin Q2 FY2026 Results. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_06112025185216_PressReleaseQ2FY26.pdf (published 6 Nov 2025)
- S23: Press release: Lupin Q1 FY2026 Results. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_05082025205039_SEPressRelease05082025.pdf (published 5 Aug 2025)
- S24: Press release: Lupin FY2025 Results. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_14052025224619_NSELetterwithPressRelease14052025.pdf (published 14 May 2025)
- S25: Press release (revised): Lupin Q3 FY2025 Results. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_12022025145819_NSEIntimation.pdf (published 12 Feb 2025)
- S26: Investor presentation Q2 FY2027. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_04112026014841_SE_Intimation_Investor_Presentation_04112026.pdf (published 4 Nov 2026)
- S27: Transcript of Q2 FY2027 earnings call (held 4 Nov 2026). Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_06112026203743_SE_Intimation_of_Investor_Meet_Transcript.pdf (published 6 Nov 2026)
- S28: Transcript of Q1 FY2027 earnings call (held 7 Aug 2026). Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_12082026174715_SE_Letter_signed.pdf (published 12 Aug 2026)
- S29: Transcript of Q4 FY2026 earnings call (held 8 May 2026). Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_14052026170631_SE_Intimation_of_Investor_Meet_Transcript.pdf (published 14 May 2026)
- S30: Transcript of Q3 FY2026 earnings call (held 13 Feb 2026). Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_17022026171711_SE_Intimation_of_Investor_Meet_Transcript.pdf (published 17 Feb 2026)
- S31: ICRA rationale: Lupin Limited, [ICRA]A1+ reaffirmed (Rs 3,000 crore short-term facilities). ICRA Limited. https://www.icra.in/Rating/GetRationalReportFilePdf?id=144126 (published 8 Jul 2026)
- S32: Shareholding pattern as of 30 Sep 2026 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1741171_19102026114146_WEB.xml (published 19 Oct 2026)
- S33: Shareholding pattern as of 30 Jun 2026 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1698021_21072026020405_WEB.xml (published 21 Jul 2026)
- S34: Shareholding pattern as of 31 Mar 2026 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1655255_20042026054102_WEB.xml (published 20 Apr 2026)
- S35: Shareholding pattern as of 31 Dec 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1605603_20012026041357_WEB.xml (published 20 Jan 2026)
- S36: Shareholding pattern as of 30 Sep 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1551887_17102025040212_WEB.xml (published 17 Oct 2025)
- S37: Shareholding pattern as of 30 Jun 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1486998_18072025061900_WEB.xml (published 18 Jul 2025)
- S38: Shareholding pattern as of 31 Mar 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_197454_1415891_16042025042212_WEB.xml (published 16 Apr 2025)
- S39: Shareholding pattern as of 31 Dec 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_194759_1346349_15012025052339_WEB.xml (published 15 Jan 2025)
- S40: Shareholding pattern as of 30 Sep 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_191275_1261926_08102024050256_WEB.xml (published 8 Oct 2024)
- S41: Shareholding pattern as of 30 Jun 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_189194_1181608_12072024122704_WEB.xml (published 12 Jul 2024)
- S42: Shareholding pattern as of 31 Mar 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_186307_1087499_11042024115426_WEB.xml (published 11 Apr 2024)
- S43: Shareholding pattern as of 31 Dec 2023 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_183876_1016980_11012024054945_WEB.xml (published 11 Jan 2024)
- S44: Reg 30: Nanomi B.V. agreement to acquire VISUfarma B.V.. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_29092025064353_Lupin_SE_Intimation_29092025_Visufarma.pdf (published 29 Sep 2025)
- S45: Reg 30: completion of VISUfarma B.V. acquisition. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_01042026171602_SEintimation_Updates_on_Visufarma.pdf (published 1 Apr 2026)
- S46: Reg 30: agreement to acquire minority shareholding in Multicare Pharmaceuticals Philippines. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_01042026183938_SEIntimation_Signing_of_Definitive_Agreements.pdf (published 1 Apr 2026)
- S47: Reg 30: Mirabegron settlement and licence agreement with Astellas. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_10022026073736_Settlement_Mirabegron_Final.pdf (published 10 Feb 2026)
- S48: Reg 30: settlement with Humana in In Re Generic Pharmaceuticals Antitrust Litigation. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_17042026064355_SEIntimation_InReGenericSettlement.pdf (published 17 Apr 2026)
- S49: Reg 30: appointment of Deloitte Haskins & Sells as statutory auditors. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_07052026211828_SE_Intimation-Other_Matters.pdf (published 7 May 2026)
- S50: Reg 30: US District Court (Delaware) order in Myrbetriq patent case. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_16042025213636_NSEintimation16042025.pdf (published 16 Apr 2025)
- S51: Reg 30: oncology programmes licensed to Kaveri Therapeutics for an 82.2% stake. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_21072026072213_Lupin-SE_Intimation_Lupin-Kaveri-21072026.pdf (published 21 Jul 2026)
- S52: Reg 30: US FDA inspection of Goa facility closed with Form 483 (one observation). Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_24102026141953_SEintimation_Goa_24102026.pdf (published 24 Oct 2026)
- S53: Reg 30: appointment of Akhil Gupta as independent director. Lupin Ltd (filed with NSE/BSE). https://nsearchives.nseindia.com/corporate/Lupin2_04112026011040_SE_Intimation_appointment_of_AG.pdf (published 4 Nov 2026)
